Every Form 4 that Abbott Laboratories (ABT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABT filings page.
ABBOTT LABORATORIES executive Daniel Gesua Sive Salvadori reported awards of equity-based compensation. He received an option to buy 89,226 Abbott shares at an exercise price of $0.00 per share under the 2017 Incentive Stock Program, with the option becoming exercisable in three equal annual installments of 29,742 shares on February 24, 2027, February 24, 2028, and February 24, 2029. He also acquired 21,644 common shares as a performance-based restricted stock award with a three-year term, where no more than one-third of the award can vest in any one year, subject to Abbott reaching a minimum return on equity target, and the award allows shares to be withheld to cover taxes.
ABBOTT LABORATORIES executive Louis H. Morrone reported equity awards granted on February 24, 2026. He acquired an option to buy 63,561 Abbott shares at an exercise price of $0.00 per share and a grant of 15,418 common shares, both reported as direct ownership.
The 15,418-share award is performance-based restricted stock under the Abbott Laboratories 2017 Incentive Stock Program with a 3‑year term, where no more than one‑third can vest in any year and vesting depends on Abbott reaching a minimum return on equity target, and it allows shares to be withheld for taxes. The stock option, also under the 2017 Incentive Stock Program, was granted in a transaction exempt from Section 16 under Rule 16b‑3 and becomes exercisable in three equal annual installments of 21,187 shares on February 24, 2027, February 24, 2028, and February 24, 2029. The filing also notes an indirect holding of 12 Abbott shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive vice president Mary K. Moreland reported equity awards on common stock. She received an employee stock option covering 57,512 shares that vests in three annual installments starting February 24, 2027, and a performance-based restricted stock award of 13,951 shares with a three-year term tied to return-on-equity targets.
Abbott Laboratories executive John A. McCoy Jr., Vice President and Controller, reported equity awards on February 24, 2026. He acquired an employee stock option for 22,151 options with no purchase price, which vests in three annual installments beginning in 2027. He also received a performance-based restricted stock award of 5,373 common shares that can vest over three years if Abbott meets a minimum return-on-equity target, with shares eligible to be withheld for taxes. Separately, he reported 58 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust as of that date.
Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades. He acquired 344,066 options with a zero-dollar grant price under the Abbott Laboratories 2017 Incentive Stock Program, scheduled to become exercisable in three equal annual installments starting on February 24, 2027.
Ford also received a performance-based restricted stock award of 83,464 common shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target. An additional 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Lisa D. Earnhardt, EVP and Group President, reported equity awards on February 24, 2026. She was granted stock options covering 111,533 options and a performance-based restricted stock award of 27,056 common shares under the Abbott Laboratories 2017 Incentive Stock Program.
The restricted stock award has a three-year term, with no more than one-third vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for taxes. The stock option becomes exercisable in increments of 37,177 and 37,178 shares on February 24, 2027, February 24, 2028, and February 24, 2029.
Cushman Elizabeth C. reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Elizabeth C. Cushman, EVP, GC and Secretary, reported equity awards on February 24, 2026. She received an employee stock option for 61,964 options under the Abbott 2017 Incentive Stock Program, exercisable in three annual installments starting in 2027. She was also granted 15,031 performance-based restricted shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target and allowing shares to be withheld for taxes.
ABBOTT LABORATORIES executive Philip P. Boudreau, EVP and CFO, reported equity awards. On February 24, 2026, he acquired an employee stock option for 115,413 shares with no exercise price shown here, granted under the Abbott Laboratories 2017 Incentive Stock Program and scheduled to become exercisable in three equal annual installments beginning February 24, 2027.
On the same date, he also received a performance-based restricted stock award of 27,997 common shares without par value, with a three‑year term and no more than one‑third vesting in any year, contingent on Abbott reaching a minimum return on equity target and allowing share withholding for taxes. Following these awards, he directly owned 78,613 common shares and indirectly held 366 shares through an Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Abbott Laboratories director Daniel J. Starks reported purchasing additional common shares of the company. On February 4, 2026, he bought 4,967 common shares at a weighted average price of $109.1388 and 5,033 common shares at a weighted average price of $108.3328.
Following these transactions, Starks beneficially owns 6,738,817 Abbott common shares directly. He also reports 258 common shares held indirectly through the Alynne Starks 2012 Irrevocable Trust, for which he serves as sole trustee.
Abbott Laboratories insider activity centers on a trust-related share transaction. The Ford Family Trust, for which Chairman and CEO Robert B. Ford serves as co-trustee, reported a transaction involving 18,800 Abbott common shares on January 23, 2026 at a weighted average price of $107.1259 per share, executed in multiple trades between $106.735 and $107.485. After this activity, the trust held 216,203 Abbott shares indirectly attributed to Ford, while a separate line shows 253,305 Abbott shares held directly in his name.
Abbott Laboratories director John G. Stratton reported compensation-related activity in company-linked instruments. On 12/31/2025, he acquired 313 stock equivalent units at $125.29 each, recorded as a derivative security tied to Abbott common shares. After this transaction, he beneficially owned 13,034 stock equivalent units directly.
The filing explains that these units represent director fees credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash at about age 65 or upon retirement from the board. The units earn the same return as if the fees were invested in Abbott shares, and the reported balance also reflects units accumulated through a dividend reinvestment feature.
Abbott Laboratories director Michael F. Roman reported routine equity-based compensation activity. On 12/31/2025, he acquired 301 stock equivalent units tied to Abbott common shares at a listed price of $125.29 per share equivalent. After this transaction, he held 5,882 derivative securities, reported as directly owned.
According to the disclosure, these stock equivalent units represent director fees credited to a stock equivalent unit account and are generally paid in cash at age 65 or upon retirement from the board. The units are structured to earn the same return as if the fees were invested in Abbott shares, and the balance also reflects units acquired through a dividend reinvestment feature.
Abbott Laboratories director reports routine stock-based compensation. A director of Abbott Laboratories reported a Form 4 transaction dated 12/31/2025 involving derivative securities in the form of stock equivalent units. The filing shows an acquisition of 263 stock equivalent units at a reference price of $125.29 per unit, each economically linked to one Abbott common share. Following this transaction, the director held 5,208 derivative securities in total, reported as directly owned.
According to the explanation, these units represent director fees credited to a stock equivalent unit account under a grantor trust, generally payable in cash at about age 65 or upon retirement from the board, and they earn the same return as if the fees were invested in Abbott shares. The balance also includes units accumulated through a dividend reinvestment feature.
Abbott Laboratories director reports stock-based board fees. Director Robert J. Alpern acquired 62 stock equivalent units on 12/31/2025 as reported derivative securities tied to Abbott common shares. The units were credited at a reference price of $125.29 per underlying share and are held in a stock equivalent unit account established by the director.
After this transaction, Alpern beneficially owns 10,409 derivative securities representing stock equivalent units, held directly. These director fees are generally paid in cash at about age 65 or upon retirement from the board, and the units are designed to earn the same return as if the fees were invested in Abbott shares, including additional units from a dividend reinvestment feature.
Abbott Laboratories executive reports equity transaction in company stock. A reporting person serving as EVP and Group President of Abbott Laboratories (ticker ABT) filed a Form 4 covering activity on 12/11/2025. The filing shows a transaction in Abbott common shares without par value, coded "G" under the transaction code and marked as a disposition of 1,536 shares at a price of $123.28 per share.
Following this transaction, the reporting person is shown as beneficially owning 132,233 Abbott common shares in direct ownership form. The filing is made as an individual Form 4 for one reporting person and is signed by an attorney-in-fact on 12/12/2025.
Abbott Laboratories reported an insider transaction by a senior executive. A Senior Vice President filed a Form 4 disclosing the sale of 1,586 common shares of Abbott Laboratories on 11/25/2025. The shares were sold at a weighted average price of $128.0218 per share, with individual trades executed in a range from $128.02 to $128.06.
Following this sale, the reporting person beneficially owns 30,384 Abbott common shares, held directly. The filing notes that detailed breakdowns of the individual sale prices within the reported range are available upon request from Abbott Laboratories, its security holders, or the SEC staff.